1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Serobian, A. Thomas, D.S. Ball, G.E. Denny, W.A. Wakelin, L.P.G. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C10 H14 N5 O6 P 331.222 y 2'-DEOXYADENOSINE-5'-MONOPHOSPHATE DNA linking C9 H14 N3 O7 P 307.197 y 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE DNA linking C10 H14 N5 O7 P 347.221 y 2'-DEOXYGUANOSINE-5'-MONOPHOSPHATE DNA linking C10 H15 N2 O8 P 322.208 y THYMIDINE-5'-MONOPHOSPHATE DNA linking C34 H38 N8 O2 4 590.718 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM non-polymer US Biopolymers BIPMAA 0161 0006-3525 101 1099 10.1002/BIP.22513 24898663 The Solution Structure of Bis(Phenazine-1-Carboxamide)-DNA Complexes: Mln 944 Binding Corrected and Extended. 2014 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 THE DNA CONFORMATION IS IN THE FORM OF B-DNA. 2425.629 DNA 2 syn polymer 590.718 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM 1 syn non-polymer no no (DT)(DA)(DT)(DG)(DC)(DA)(DT)(DA) TATGCATA A,B polydeoxyribonucleotide n n n n n n n n 20.580 1 20 A 1 B 16 -8.538 A_DT1:DA16_B 1 -2.072 -0.384 -0.431 0.149 8.768 1 20 A 2 B 15 0.322 A_DA2:DT15_B 2 -11.777 0.147 0.121 -0.025 6.401 1 20 A 3 B 14 -5.283 A_DT3:DA14_B 3 -11.104 -0.287 0.010 0.042 -0.957 1 19 A 4 B 13 -0.237 A_DG4:DC13_B 4 -8.007 0.034 0.122 -0.060 -4.085 1 19 A 5 B 12 1.068 A_DC5:DG12_B 5 -9.501 0.203 0.218 -0.026 -3.027 1 20 A 6 B 11 -5.246 A_DA6:DT11_B 6 0.373 0.159 0.177 0.053 5.664 1 20 A 7 B 10 2.924 A_DT7:DA10_B 7 -7.233 -0.145 0.260 -0.055 19.716 1 20 A 8 B 9 1.545 A_DA8:DT9_B 8 -9.077 0.002 -0.007 -0.020 3.992 41.621 A A 1 2 45.118 B B 16 15 4.359 29.161 -0.311 1.188 AA_DT1DA2:DT15DA16_BB 1 -0.091 0.140 30.027 -2.980 0.423 3.518 32.851 A A 2 3 -7.389 B B 15 14 3.434 -4.167 -0.641 -0.698 AA_DA2DT3:DA14DT15_BB 2 -1.436 2.546 32.562 -0.472 0.871 6.332 12.908 A A 3 4 -15.157 B B 14 13 6.955 -3.303 -0.328 0.377 AA_DT3DG4:DC13DA14_BB 3 -4.285 19.662 11.724 9.575 -8.785 3.241 38.767 A A 4 5 -5.037 B B 13 12 3.333 -3.339 0.394 0.764 AA_DG4DC5:DG12DC13_BB 4 -1.525 2.300 38.599 1.562 -0.782 5.970 15.216 A A 5 6 -20.421 B B 12 11 6.830 -5.284 1.060 0.809 AA_DC5DA6:DT11DG12_BB 5 -1.674 6.468 14.176 11.701 -6.741 3.193 22.312 A A 6 7 -2.964 B B 11 10 3.227 -1.145 0.566 -0.338 AA_DA6DT7:DA10DT11_BB 6 -1.561 4.040 22.229 -0.453 -2.038 3.348 45.475 A A 7 8 2.759 B B 10 9 3.275 2.129 0.533 0.902 AA_DT7DA8:DT9DA10_BB 7 4.569 -5.922 45.209 0.976 -0.280 repository Initial release Structure summary Structure summary Database references 1 0 2013-08-21 1 1 2013-08-28 1 2 2013-09-04 1 3 2014-09-03 SOLUTION STRUCTURE OF MLN 944-DNA COMPLEXES THE SOLUTION STRUCTURE OF THE MLN 944-D(TACGCGTA)2 COMPLEX PDBE Y PDBE 2013-07-30 REL XR2 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM 32630 SYNTHETIC CONSTRUCT sample NONE DISTANCE RESTRAINTS 1 1 NOESY COSY TOCSY 31P HSQC 15N HSQC 80 mM 5.0 pH 1.0 atm 288.0 K AMBER - MOLECULAR DYNAMICS 10% WATER/90% D2O D.A.CASE,ET.AL. refinement AMBER structure solution TOPSPIN 3.1 700 Bruker Avance XR2 17 2 XR2 XR2 17 A DT 1 n 1 DT 1 A DA 2 n 2 DA 2 A DT 3 n 3 DT 3 A DG 4 n 4 DG 4 A DC 5 n 5 DC 5 A DA 6 n 6 DA 6 A DT 7 n 7 DT 7 A DA 8 n 8 DA 8 A DT 9 n 1 DT 9 B DA 10 n 2 DA 10 B DT 11 n 3 DT 11 B DG 12 n 4 DG 12 B DC 13 n 5 DC 13 B DA 14 n 6 DA 14 B DT 15 n 7 DT 15 B DA 16 n 8 DA 16 B author_and_software_defined_assembly PQS 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A DT 1 0.082 SIDE CHAIN 1 A DA 8 0.064 SIDE CHAIN 1 B DT 9 0.065 SIDE CHAIN 1 B DA 10 0.073 SIDE CHAIN 1 B DT 15 0.084 SIDE CHAIN 1 -3.21 0.50 117.00 113.79 A A A C4 C5 C6 DA DA DA 2 2 2 N 1 3.22 0.50 117.70 120.92 A A A C5 C6 N1 DA DA DA 2 2 2 N 1 -4.51 0.60 118.60 114.09 A A A N1 C6 N6 DA DA DA 2 2 2 N 1 3.19 0.30 108.30 111.49 A A A O4' C1' N9 DG DG DG 4 4 4 N 1 3.91 0.30 108.30 112.21 A A A O4' C1' N1 DC DC DC 5 5 5 N 1 -4.24 0.70 121.90 117.66 A A A N3 C2 O2 DC DC DC 5 5 5 N 1 4.19 0.30 108.30 112.49 A A A O4' C1' N9 DA DA DA 6 6 6 N 1 -3.17 0.50 117.00 113.83 A A A C4 C5 C6 DA DA DA 6 6 6 N 1 3.80 0.50 117.70 121.50 A A A C5 C6 N1 DA DA DA 6 6 6 N 1 -4.06 0.60 118.60 114.54 A A A N1 C6 N6 DA DA DA 6 6 6 N 1 2.87 0.30 108.30 111.17 A A A O4' C1' N1 DT DT DT 7 7 7 N 1 -3.14 0.50 117.00 113.86 A A A C4 C5 C6 DA DA DA 8 8 8 N 1 3.47 0.50 117.70 121.17 A A A C5 C6 N1 DA DA DA 8 8 8 N 1 -4.71 0.60 118.60 113.89 A A A N1 C6 N6 DA DA DA 8 8 8 N 1 3.45 0.30 108.30 111.75 B B B O4' C1' N1 DT DT DT 9 9 9 N 1 -3.75 0.50 117.00 113.25 B B B C4 C5 C6 DA DA DA 10 10 10 N 1 3.35 0.50 117.70 121.05 B B B C5 C6 N1 DA DA DA 10 10 10 N 1 -5.22 0.60 118.60 113.38 B B B N1 C6 N6 DA DA DA 10 10 10 N 1 -3.72 0.60 122.90 119.18 B B B C6 C5 C7 DT DT DT 11 11 11 N 1 3.01 0.30 108.30 111.31 B B B O4' C1' N9 DG DG DG 12 12 12 N 1 2.39 0.30 108.30 110.69 B B B O4' C1' N9 DA DA DA 14 14 14 N 1 -3.18 0.50 117.00 113.82 B B B C4 C5 C6 DA DA DA 14 14 14 N 1 3.81 0.50 117.70 121.51 B B B C5 C6 N1 DA DA DA 14 14 14 N 1 -4.23 0.60 118.60 114.37 B B B N1 C6 N6 DA DA DA 14 14 14 N 1 1.83 0.30 108.30 110.13 B B B O4' C1' N9 DA DA DA 16 16 16 N 1 -3.29 0.50 117.00 113.71 B B B C4 C5 C6 DA DA DA 16 16 16 N 1 4.03 0.50 117.70 121.73 B B B C5 C6 N1 DA DA DA 16 16 16 N 1 -4.16 0.60 118.60 114.44 B B B N1 C6 N6 DA DA DA 16 16 16 N 5'-D(*TP*AP*TP*GP*CP*AP*TP*A)-3', 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM The Solution Structure of the MLN 944-d(TATGCATA)2 Complex 1 N N 1 N N 2 N N hydrog WATSON-CRICK A DT 1 A N3 DT 1 1_555 B DA 16 B N1 DA 8 1_555 hydrog WATSON-CRICK A DT 1 A O4 DT 1 1_555 B DA 16 B N6 DA 8 1_555 hydrog WATSON-CRICK A DA 2 A N1 DA 2 1_555 B DT 15 B N3 DT 7 1_555 hydrog WATSON-CRICK A DA 2 A N6 DA 2 1_555 B DT 15 B O4 DT 7 1_555 hydrog WATSON-CRICK A DT 3 A N3 DT 3 1_555 B DA 14 B N1 DA 6 1_555 hydrog WATSON-CRICK A DT 3 A O4 DT 3 1_555 B DA 14 B N6 DA 6 1_555 hydrog WATSON-CRICK A DG 4 A N1 DG 4 1_555 B DC 13 B N3 DC 5 1_555 hydrog WATSON-CRICK A DG 4 A N2 DG 4 1_555 B DC 13 B O2 DC 5 1_555 hydrog WATSON-CRICK A DG 4 A O6 DG 4 1_555 B DC 13 B N4 DC 5 1_555 hydrog WATSON-CRICK A DC 5 A N3 DC 5 1_555 B DG 12 B N1 DG 4 1_555 hydrog WATSON-CRICK A DC 5 A N4 DC 5 1_555 B DG 12 B O6 DG 4 1_555 hydrog WATSON-CRICK A DC 5 A O2 DC 5 1_555 B DG 12 B N2 DG 4 1_555 hydrog WATSON-CRICK A DA 6 A N1 DA 6 1_555 B DT 11 B N3 DT 3 1_555 hydrog WATSON-CRICK A DA 6 A N6 DA 6 1_555 B DT 11 B O4 DT 3 1_555 hydrog WATSON-CRICK A DT 7 A N3 DT 7 1_555 B DA 10 B N1 DA 2 1_555 hydrog WATSON-CRICK A DT 7 A O4 DT 7 1_555 B DA 10 B N6 DA 2 1_555 hydrog WATSON-CRICK A DA 8 A N1 DA 8 1_555 B DT 9 B N3 DT 1 1_555 hydrog WATSON-CRICK A DA 8 A N6 DA 8 1_555 B DT 9 B O4 DT 1 1_555 DNA BIS(PHENAZINE-1-CARBOXAMIDES), MLN 944, DNA, INTERCALATION, DRUG DESIGN, ANTICANCER DRUG. 4BZU PDB 1 4BZU 1 8 4BZU 1 8 4BZU A 1 1 8 9 16 4BZU 9 16 4BZU B 1 1 8 BINDING SITE FOR RESIDUE XR2 A 17 Software 8 A DT 3 A DT 3 8 1_555 A DG 4 A DG 4 8 1_555 A DC 5 A DC 5 8 1_555 A DA 6 A DA 6 8 1_555 B DT 11 B DT 3 8 1_555 B DG 12 B DG 4 8 1_555 B DC 13 B DC 5 8 1_555 B DA 14 B DA 6 8 1_555 1 P 1